---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-011443"
form_type: "8-K"
ticker: "PVCT"
cik: "0000315545"
company_name: "PROVECTUS BIOPHARMACEUTICALS, INC."
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:26:34.983813+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Provectus licenses University of Miami's rose bengal PDAT for eye infections; will form spinout

## Summary
- Exclusive worldwide license for photodynamic antimicrobial therapy (PDAT) using rose bengal sodium to treat bacterial, fungal, and acanthamoeba keratitis.
- Upfront fee of $10k; 10% royalty on net sales; annual maintenance fees of $1k (years 1-4) then $10k; development milestones up to $55k.
- Company to form a majority-owned NewCo within one year; University gets 5% equity and up to 30% of sublicense income depending on clinical phase.
- Technology supported by two international randomized clinical trials (NCT05110001, NCT06271772) for acanthamoeba/fungal and bacterial keratitis.
- Provectus will supply pharmaceutical-grade rose bengal sodium to NewCo exclusively.

## SEC filing metadata
- accession: 0001493152-24-011443
- form_type: 8-K
- ticker: PVCT
- cik: 0000315545
- company_name: PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315224011443/0001493152-24-011443-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315224011443/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-011443
- JSON: https://secwatch.observer/filing/0001493152-24-011443.json
- Plain text: https://secwatch.observer/filing/0001493152-24-011443.txt

## Key facts
- Material Agreements
  PROVECTUS BIOPHARMACEUTICALS, INC. entered into Exclusive License Agreement with University of Miami (effective 2024-03-21).
  - Action: entry
  - Agreement: license
  - Counterparty: University of Miami
  - Effective: 2024-03-21
  source text: On March 21, 2024, Provectus Biopharmaceuticals, Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with the University of Miami (the “University”) for the license and development of the University’s intellectual property related to photodynamic antimicrobial therapy in ophthalmology.
  evidence_url: https://www.sec.gov/Archives/edgar/data/315545/000149315224011443/0001493152-24-011443-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.